Market Access News | pharmaphorum

News

Lilly holds off on tirzepatide filing in obesity, waiting fo...

Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide in obesity, rather than filing on the strength of its first, positive study.

News

2019-Gene-Therapy-Muscular-Dystrophy_ProgFeature_IMG

Solid Biosciences acquires AavantiBio, conducts $75 million ...

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a

News

AstraZeneca pays record 660% premium for gene editing compan...

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately

News

Translarna not approved by NICE for DMD on NHS

In draft guidance published on Friday, it emerged NICE does not recommend PTC Therapeutics’ Translarna (ataluren) for the treatment of Duchenne muscular dystrophy (DMD) caused by a nonsense

News

Illustration of a nerve cell on a colored background with light effects

Relief for Amylyx as FDA clears controversial ALS drug Relyv...

Patient organisations have been celebrating the FDA approval yesterday of Amylyx' amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings tha

News

FDA clears Dupixent as first drug for rare skin disorder

Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin di

Lilly holds off on tirzepatide filing in obesity, waiting fo...

Solid Biosciences acquires AavantiBio, conducts $75 million ...

AstraZeneca pays record 660% premium for gene editing compan...

Translarna not approved by NICE for DMD on NHS

Relief for Amylyx as FDA clears controversial ALS drug Relyv...

FDA clears Dupixent as first drug for rare skin disorder

Policy in Focus: What’s new with CMS drug price negotiation,...

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks